Kezar Life Sciences saw the highest growth of 0.99% in patent filings and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Kezar Life Sciences’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Kezar Life Sciences has been focused on protecting inventions in China(CN) with two publications in Q2 2024
The China(CN) Patent Office dominates the patent grants with nearly 50% of grants. The South Korea(KR), Argentina(AR), China(CN), and United States(US) patent Office are among the top ten patent offices where Kezar Life Sciences is filings its patents. Among the top granted patent authorities, Kezar Life Sciences has 50% of its grants in China(CN), 25% in South Korea(KR) and 25% in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Kezar Life Sciences
Patents related to rare diseases lead Kezar Life Sciences's portfolio
Kezar Life Sciences has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Inflammation related patents lead Kezar Life Sciences portfolio
Kezar Life Sciences has highest number of patents in inflammation.
For comprehensive analysis of Kezar Life Sciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

